A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme KMT2D as a key epigenetic regulator in prostate cancer. Their study published in Cancer Research reveals that KMT2D plays a central role in shaping how prostate tumors grow, survive, and respond to therapy.
This article was originally published on MedicalXpress.com

